Evidence map›Paper›PMID 38602886›Full record

ArticleMMWR. Morbidity and mortality weekly report2024

Measles - United States, January 1, 2020-March 28, 2024.

Adria D Mathis, Kelley Raines, Nina B Masters, Thomas D Filardo, Gimin Kim, Stephen N Crooke, Bettina Bankamp, Paul A Rota, David E Sugerman

Abstract read
In one paragraph

Article in MMWR. Morbidity and mortality weekly report, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Article
  2. The health and economic repercussions of declining MMR coverage in the United States.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. [Global Measles Outbreaks].Jugan geon-gang gwa jilbyeong · 2024
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Adria D MathisDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC.
Kelley RainesDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC.
Nina B MastersDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC.
Thomas D FilardoDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC.
Gimin KimDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC.
Stephen N CrookeDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC.
Bettina BankampDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC.
Paul A RotaDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC.
David E SugermanDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Measles is a highly infectious febrile rash illness and was declared eliminated in the United States in 2000. However, measles importations continue to occur, and U.S. measles elimination status was threatened in 2019 as the result of two prolonged outbreaks among undervaccinated communities in New York and New York City. To assess U.S. measles elimination status after the 2019 outbreaks and to provide context to understand more recent increases in measles cases, CDC analyzed epidemiologic and laboratory surveillance data and the performance of the U.S. measles surveillance system after these outbreaks. During January 1, 2020-March 28, 2024, CDC was notified of 338 confirmed measles cases; 97 (29%) of these cases occurred during the first quarter of 2024, representing a more than seventeenfold increase over the mean number of cases reported during the first quarter of 2020-2023. Among the 338 reported cases, the median patient age was 3 years (range = 0-64 years); 309 (91%) patients were unvaccinated or had unknown vaccination status, and 336 case investigations included information on ≥80% of critical surveillance indicators. During 2020-2023, the longest transmission chain lasted 63 days. As of the end of 2023, because of the absence of sustained measles virus transmission for 12 consecutive months in the presence of a well-performing surveillance system, U.S. measles elimination status was maintained. Risk for widespread U.S. measles transmission remains low because of high population immunity. However, because of the increase in cases during the first quarter of 2024, additional activities are needed to increase U.S. routine measles, mumps, and rubella vaccination coverage, especially among close-knit and undervaccinated communities. These activities include encouraging vaccination before international travel and rapidly investigating suspected measles cases.

Indexed as

MeaslesAdolescentAdultChildChild, PreschoolDisease OutbreaksHumansInfantInfant, NewbornMeasles-Mumps-Rubella VaccineMeasles virusMiddle AgedNew York CityUnited StatesVaccinationVaccination CoverageMeasles-Mumps-Rubella Vaccine

Identifiers

PMID38602886
PMCPMC11008791

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.